Beacon: for rare diseases, the University of Sheffield and the University of Hull have joined 21 European organisations for the REMEDi4ALL project.
What is REMEDi4ALL?
REMEDi4ALL is a new flagship EU-funded research initiative to drive the repurposing of medicines across the UK and Europe.
The REMEDi4ALL project will repurpose medicines to treat some of the world’s rarest and most neglected conditions, such as rare genetic diseases, poorly understood cancers and infectious diseases.
The REMEDi4ALL consortium, led by EATRIS (the European infrastructure for translational medicine), will work in partnership with patient groups and an international community of those interested or actively engaged in drug repurposing to change the repurposing landscape. The REMEDi4ALL project will make it easier for repurposed medicines to succeed and reach patients faster.
Our role in the project
We’ll be bringing patient input to the heart of the REMEDi4ALL project!
We’ll be responsible for leading the consortium’s educational programme on drug repurposing to support the international drug repurposing community.
Watch this space!
The patient perspective will be central to the decision-making process and placed firmly at the heart of this ground-breaking project.
REMEDi4ALL is a hugely exciting initiative, with the potential to create a truly effective pathway to develop repurposed drugs for often neglected conditions. Beacon is excited to be part of this consortium, and we will work to highlight both the central role repurposing can play in the future of drug development, and the huge benefit of patient input into this crucial research.
Did you know?
EATRIS’ Operations & Finance Director, Anton Ussi, will be speaking about REMEDi4ALL at our Drug Repurposing for Rare Diseases Conference in London on 10th October 2022?
Register now to learn more about this UK and EU collaboration and drug repurposing project at #DrugRepo22!